Yu.I. Feshchenko

Yu.I. Feshchenko

Auto-generated profile, based on publicly available information

Yu.I. Feshchenko

NAMS Ukraine, Kiev, Ukraine

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2019 in Infusion & Chemotherapy
Verified
Journal Article
Open access
YFY. I. Feshchenko
Y. I. Feshchenko
VMV. M. Melnyk
V. M. Melnyk
MGM. I. Gumeniuk
M. I. Gumeniuk
MLM. I. Lynnyk
M. I. Lynnyk
Purpose of the study. Analysis of epidemic situation for tuberculosis in Ukraine. Material and methods. Official materials of annual reports of medical institutions of the Ministry of Health of Ukraine, materials of the analytical and statistical reference book “Tuberculosis in Ukraine” (2018). Results. Despite the decrease in the incidence of tuberculosis over the past 5 years, the statistical indicators remain high, exceeding the epidemic threshold, that is, the epidemic situation with this infectious disease remains difficult. Forecasting using trends indicates that no significant epidemic dynamics are expected in the next 5 years. There is an increase in the incidence of tuberculosis in combination with AIDS, mortality in patients under 1 year of observation, and the incidence of tuberculosis in contact persons. Indicators of adult coverage by preventive fluorographic examinations and tuberculin diagnostics of children aged 0-14 years continue to decline, and therefore the actual morbidity rates are much higher. All this requires urgent measures to improve the existing system of detection, diagnosis, treatment, prevention of tuberculosis.

15 December 2021 in Tuberculosis, Lung Diseases, HIV Infection
Verified
Journal Article
Closed access
PDF file
YFYu.I. Feshchenko
Yu.I. Feshchenko
NLN.A. Litvinenko
N.A. Litvinenko
NGN.V. Grankina
N.V. Grankina
MPM.V. Pogrebna
M.V. Pogrebna
YSYu.O. Senko
Yu.O. Senko
ЮФЮ.і. Фещенко
Ю.і. Фещенко
Objective — to study the effectiveness of treatment of MDR-TB (multidrug-resistant tuberculosis) and preXDR-TB/XDR-TB (pre-extensively and extensively drug resistant tuberculosis), depending on the composition of ITRs (individualized treatment regimens). Materials and methods. Тhe prospective observational study included 566 patients with MDR/preXDR-TB and XDR-TB during 2016—2020 on the scientific clinical bases of the SI «National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky NAMS of Ukraine» and ME «Kryvyi Rih Anti-tuberculosis Dispensary» Dnipropetrovsk Regional Council Department. Patients were prescribed individualized treatment regimens in cases where short (standard or modified) regimens could not be prescribed. Patients were divided into comparison groups: 469 of them were treated with antimycobacterial therapy including bedaquiline and other effective antimycobacterial drugs groups A—C (without delamanid) — group 1. And 97 patients who were treated with the inclusion of both new antimycobacterial drugs (bedaquiline and delamanid) — group 2. Results and discussion. Regardless of whether the delamanid, in addition to bedaquiline and other drugs selected for the scheme according to WHO recommendations, «effective treatment» was found in 91.3 against 88.6 % of patients. In the remote period (6-month — 4-year follow-up period) there was no recurrence of the disease, regardless of the composition of the regime. The loss of treatment effectiveness was due to deaths from non-tuberculosis reasons and those lost for follow-up. Conclusions. For highly effective treatment, individualized regimens should include bedaquidine and linezolid from group A, and for previously ineffectively treated patients, clofazimine and carbapenems must be included (possibility to include 4 or more effective AMDs in ITR). For patients with fluoroquinolone resistance, treatment should include delamanid.

15 March 2023 in Tuberculosis, Lung Diseases, HIV Infection
Verified
Journal Article
Open access
PDF file
YFYu.I. Feshchenko
Yu.I. Feshchenko
NLN.A. Lytvynenko
N.A. Lytvynenko
MPM.V. Pohrebna
M.V. Pohrebna
YSYu.O. Senko
Yu.O. Senko
ALA.S. Lafeta
A.S. Lafeta
YTYa.S. Terleeva
Ya.S. Terleeva
Мета роботи — вивчити програмні результати ефективності та переносності стандартної комбінації режиму BPaL (NIX-TB, zeNIX-TB, TB Practecal, Simplici TB) для хворих на туберкульоз із пре-широ­кою лікарською стійкістю та невдач лікування туберкульозу з множинною лікарською стійкістю в операційному дослідженні. Матеріали та методи. Лікування хворих за режимом BPaL проведено в межах проєкту МБФ «Орга­нізація оптимальних технологій у сфері охорони здоров’я» на базі Національного інституту фтизіат­рії і пульмонології імені Ф.Г. Яновського НАМН України як операційне дослідження «Пілотне дослід­ження з оцінки ефективності та безпечності антимікобактеріальної терапії BPaL в Україні». Набір тривав з листопада 2020 до березня 2022 року. Склад режиму BPaL: бедаквілін — 400 мг щоденно перших 2 тиж із наступним переходом на 200 мг через день, лінезолід — 1200 мг щоденно (з можливістю зміни дози чи відміни не раніше ніж через 4 послідовних тижні його використання), претоманід — 200 мг щоденно. Стандартна тривалість лікування — 6 міс (26 тиж або 182 дози). Тривалість лікування збільшували до 9 міс у разі позитивного результату посіву мокротиння (або реверсії) через 4 міс лікування та недостатньої динаміки через 6 міс лікування. План впровадження передбачав 135 хворих на туберкульоз із пре-широкою лікарською стійкістю або невдачею попередніх курсів без критеріїв вилучення. Результати та обговорення. Незважаючи на суттєві виклики/бар’єри, що виникли на шляху реалізації операційного дослідження, ефективність режиму BPaL, виявлена в межах проєкту, узгоджується з результатами клінічних випробувань різних варіантів режиму BPaL: успішним лікування було у 91,5 % хворих. Режим був досить безпечним: повна відміна BPaL через серйозні небажані явища (НЯ) лише у 4 хворих. Решті пацієнтів, незважаючи на НЯ різного ступеня у 81,4 % хворих, вдалося успішно завершити BPaL. Повну відміну лінезоліду зі складу BPaL проведено лише у 8,2 % хворих. Очікувано, що основними НЯ були мієлосупресія та периферична нейропатія (основні НЯ лінезоліду у високій дозі — 1200 мг/добу). Також зафіксовано гепатотоксичність майже у кожного 4-го пацієнта. Отримані нами дані узгоджуються з результатами клінічних випробувань. Таких високих результатів вдалося досягти завдяки тісній співпраці партнерів, підготовці та навчанню спеціалістів інституту, як наслідок — уважне ставлення до кожного пацієнта, ретельний моніторинг його стану та людино-орієнтований підхід. Висновки. Україна є першою країною у світі, яка провела лікування хворих на ТБ за режимом BPaL у межах операційних досліджень з гарними результатами, що сприяло ширшому використанню лікування за режимом BPaL в Україні навіть під час війни.

25 March 2021 in Infusion & Chemotherapy
Verified
Journal Article
Open access
PDF file
YFY.I. Feshchenko
Y.I. Feshchenko
SBS. Beridze
S. Beridze
DHDinh Thi Hoa
Dinh Thi Hoa
VMV.Y. Molodtsov
V.Y. Molodtsov
MGM.I. Gumeniuk
M.I. Gumeniuk
NANguyen Thi Thu Anh
Nguyen Thi Thu Anh
Adequate and effective treatment of severe pneumonia is especially relevant in present situation. The most problematic issue is infusion therapy. The current evidence and guidelines recommend balanced crystalloid infusion for patients with severe pneumonia and sepsis. The composition of Rheosorbilact® provides significant benefits in patients with severe infections, including respiratory infections. According to the results of the randomized open blinded end-point RheoSTAT-CP0698 study, administration of Rheosorbilact® to patients with pneumonia (intravenous infusion at a dose of 200-400 ml/day for 3 days) effectively improves the clinical condition, reduces the manifestations of (multi-) organ failure and endogenous intoxication. Small-volume infusion therapy promotes rapid normalization of circulating blood volume, stabilization of hemodynamics, acid-base, electrolyte and gas composition of the blood, significantly improves saturation and reduces tachypnea. The positive effect of therapy on renal function and inflammation has also been established. This therapy had a favorable safety profile (e. g., it did not lead to fluid overload, pulmonary edema, pleural effusion or other serious side effects, and was not associated with a clinically significant increase in endogenous serum lactate level). The RheoSTAT-CP0698 study substantiates the feasibility of using Rheosorbilact® in the complex treatment of pneumonia.

24 June 2020 in Infusion & Chemotherapy
Verified
Journal Article
Open access
PDF file
YFY. I. Feshchenko
Y. I. Feshchenko
BACKGROUND. Clinical course of coronavirus disease (COVID-19) in patients infected by SARS-CoV-2 varies from the absolute absence of symptoms to the extremely severe viral pneumonias with the development of acute respiratory distress syndrome. In this context, investigation of the peculiarities of disease course in dependence of viral load (VL) is very interesting. OBJECTIVE. The aim of this paper is to analyze the results of novel clinical studies, dedicated to VL estimation in different biological specimens and its correlation with the severity of COVID-19 clinical course. RESULTS AND DISCUSSION. During the first months of 2020 there were published some scientific studies, which analyzed the association between VL and the severity of COVID-19 clinical course. It was established that VL was high at the beginning of the disease; in the sputum its value was higher than in throat and nasal swabs. In comparison to the mild course of COVID-19, severe course is characterized by higher VL and longer release of the virus into the environment. Apart from that, high VL is associated with the significant increase of proinflammatory cytokines’ levels, risk of disease progress and unfavorable prognosis. CONCLUSIONS. VL can be considered a risk factor and the predictor of severe course of COVID-19. Measures, aimed at the effective decrease of VL on each stage of the disease, and the improvement of antiepidemic control must help to optimize the treatment and prevent the spread of infection.

20 December 2021 in JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE
Verified
Journal Article
Closed access
YFYurii Feshchenko
Yurii Feshchenko
OBOlga Bilogortseva
Olga Bilogortseva
YDYaroslava Dotsenko
Yaroslava Dotsenko
ISIryna Shekhter
Iryna Shekhter
OSOksana Sivachenko
Oksana Sivachenko
OPOksana Panasiukova
Oksana Panasiukova
Introduction. The main thrust of the global tuberculosis response for decades has been focused on tuberculosis (TB) in adults. However, this approach has failed to achieve the expected results in TB control. Therefore, WHO has changed the paradigm of TB control with a focus on childhood TB. Objective. To investigate the epidemiological situation of childhood tuberculosis in Ukraine in dynamics, to define the main factors of negative changes, and to define the directions for improvement of antituberculosis care. Materials and Methods. Epidemiological, clinical, statistical. Results. The epidemiological situation in Ukraine remains difficult. Over the past 10 years, the relapse rate of TB in adults has increased significantly, from 13.6% to 23.0%, and the number of patients with drug-resistant (DR) TB (in children by 11.0% in 2020). The volume of professional examination of children for TB decreased significantly, which led to an increase in the structure of the disease of severe forms requiring surgical treatment, and a significant under-recognition of patients and individuals with latent TB infection. Etiological verification of the diagnosis in children is very difficult. Practically 50.0% of unhealthy inpatients, even with very scrupulous examination, fail to detect MBT by any method (in Ukraine this figure reaches 70.0%). Conclusions. In spite of positive dynamics of morbidity and mortality, WHO estimations show significant underdiagnosis of TB patients in Ukraine. The relapse rate in adults and DR-TB patients of all age groups is increasing; the percentage of children under 14 years old in the age structure is increasing. Early detection of TB infection in children is extremely important for TB control in the country, which requires free access of the child population to systematic screening for TB with the Mantoux test and a new skin test with highly specific TB biomarkers (ESAT-6, CFP-10). Modern methods of molecular-genetic diagnostics of TB are quickly and efficiently implemented in NIFP, treatment of children with DR-TB with new anti-TB drugs was started. For the first time in Ukraine, the Center of surgical treatment of children with tuberculosis of the respiratory organs was established at the Institute. Keywords. TB in children, epidemiological indicators, dynamics of morbidity, drug-resistant TB, improvement of anti-TB care.